Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 12 months~* P. vivax or P. falciparum monoinfection or P.v. / P.f. mixed infection~* Presence of axillary temperature ≥ 37.5°C or history of fever during the past 24 hrs~* Ability to swallow oral medication.~* Ability and willingness to comply with the study protocol for the duration of the study~* Informed consent/assent from the patient or from a parent or guardian in the case of children.~Exclusion Criteria:~* Presence of general danger signs in children aged under 5 years or signs of severe malaria according to the definitions of WHO~* Presence of severe malnutrition~* Acute anaemia \<8g/dL~* Regular medication, which may interfere with antimalarial pharmacokinetics~* History of hypersensitivity reactions or contraindications to any of the drug(s) tested or used as alternative treatment(s)~* A positive pregnancy test or lactating

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- chloroquine primaquine 14days (Type: OTHER): P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
- artemether-lumefantrine primaquine 1day (Type: OTHER): P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
- artemether-lumefantrine primaquine 14days (Type: OTHER): mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).